A recent study observed an association between complete hematologic response (CHR) and molecular response (MR) in patients with polycythemia vera (PV) treated with ropeginterferon.
Thrombosis is a major complication in patients with polycythemia vera and a leading cause of death in this patient population.
“To prevent thrombosis in patients with PV, achieving CHR is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease-modifying effect, and its MR is currently of significant interest,” wrote the authors, led by Seug Yun Yoon of the Division of Hematology and Medical Oncology in the Department of Internal Medicine at Soonchunhyang University Seoul Hospital in South Korea. Therefore, they sought to elucidate any association between CHR and MR in patients with PV after treatment with ropeginterferon alfa-2b.